High-cost drugs in ophthalmology       

FOI REFERENCE: 24180  FOI DATE: 17^th June 2024     

1. For the 4 months from January to April 2024, how many patients received the following intra-vitreal treatments for any eye condition:

Aflibercept                                                      1593

Bevacizumab                                                  94

Brolucizumab                                                 0

Dexamethasone                                             103     

Faricimab                                                       193

Ranibizumab – Lucentis                                 31

Ranibizumab – Ongavia                                 294